KURA Stock Price History and Quote Analysis Insights for Investors
Kura Oncology, Inc.
Stock Price Today
Kura Oncology, Inc. (KURA) stock declined over -0.37%, trading at $10.67 on NASDAQ, down from the previous close of $10.71. The stock opened at $10.82, fluctuating between $10.65 and $11.08 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Company Information
| Employees | 142 |
| Beta | 0.86 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Kura Oncology, Inc. (NASDAQ: KURA) stock price is $10.67 in the last trading session. During the trading session, KURA stock reached the peak price of $11.08 while $10.65 was the lowest point it dropped to. The percentage change in KURA stock occurred in the recent session was -0.37% while the dollar amount for the price change in KURA stock was -$0.04.
The NASDAQ listed KURA is part of Biotechnology industry that operates in the broader Healthcare sector. Kura Oncology, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Kirsten Flowers
Chief Commercial Officer & Chief Corporation Strategy Officer
Mr. Pete De Spain
Senior Vice President of Investor Relations & Corporation Communications
Dr. Stephen Dale M.D.
Chief Medical Officer
Ms. Kathleen Ford
Chief Operating Officer
Mr. Thomas Doyle
Senior Vice President of Fin. & Accounting
Dr. Roger Bakale Ph.D.
Vice President and Head of CMC, Clinical & Commercial Manufacturing
Mr. James E. Basta J.D., Esq.
Chief Compliance Officer & Corporation Sec.
Ms. Teresa Brophy Bair Esq., J.D.
Chief Legal Officer & Corporation Sec.
Ms. Maureen Clancy M.B.A.
Vice President and Global Head of Program Leadership & Project Management
Dr. Troy Edward Wilson J.D., Ph.D.
Co-Founder & Chairman
KURA's closing price is 10.23% higher than its 52-week low of $9.68 where as its distance from 52-week high of $24.17 is -55.85%.
Number of KURA employees currently stands at 142.
Official Website of KURA is: https://kuraoncology.com
KURA could be contacted at phone 858 500 8800 and can also be accessed through its website. KURA operates from 12730 High Bluff Drive, San Diego, CA 92130, United States.
KURA stock volume for the day was 1.28M shares. The average number of KURA shares traded daily for last 3 months was 1.24M.
The market value of KURA currently stands at $829.74M with its latest stock price at $10.67 and 77.76M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com